Cardiovascular
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes–global burden of disease and forecasted trends. J Epidemiol Global Health. 2020;10(1):107.
Google Scholar
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
Google Scholar
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
Google Scholar
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347–57.
Google Scholar
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249–59.
Google Scholar
Kosiborod M, Lam CS, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh S-Y, Thuresson M, Chen H. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628–39.
Google Scholar
Chatur S, Cunningham JW, Vaduganathan M, Mc Causland FR, Claggett BL, Desai AS, Miao ZM, Jhund PS, de Boer RA, Hernandez AF. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: insights from the DELIVER trial. Eur J Heart Fail. 2023. https://doi.org/10.1002/ejhf.2915.
Google Scholar
Chatur S, Vaduganathan M, Claggett B, Vardeny O, Desai AS, Jhund PS, de Boer RA, Lam CS, Kosiborod MN, Shah SJ. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur Heart J. 2023. https://doi.org/10.1093/eurheartj/ehad283.
Google Scholar
Butler J, Usman MS, Filippatos G, Ferreira JP, Böhm M, Brueckmann M, Januzzi JL, Kaul S, Piña IL, Ponikowski P. Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-Preserved trial. JAMA Cardiol. 2023. https://doi.org/10.1001/jamacardio.2023.
Google Scholar
Butt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, Claggett BL, Hernandez AF, Lam CS, Inzucchi SE. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023. https://doi.org/10.1093/eurheartj/ehad276.
Google Scholar
Lahnwong S, Chattipakorn SC, Chattipakorn N. Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 2018;17(1):1–17.
Google Scholar
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
Google Scholar
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner–La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.
Google Scholar
McMurray JJ, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Google Scholar
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.
Google Scholar
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–58.
Google Scholar
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RH. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. 2019;393(10166):31–9.
Google Scholar
Yang A-Y, Chen H-C. Comparative assessment of the long-term effectiveness and safety of dapagliflozin and empagliflozin as add-on therapy to hypoglycemic drugs in patients with type 2 diabetes. J Diabetes Res. 2022;2022:2420857.
Google Scholar
Blonde L, Patel C, Wu B, Chen Y-W, Pericone CD, Bookhart B. Real-world comparative effectiveness of canagliflozin versus empagliflozin and dapagliflozin in patients with type 2 diabetes in the United States. Adv Therapy. 2021;38(1):594–606.
Google Scholar
Yang A-Y, Chen H-C. Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin. Int J Clin Pharm. 2021;43(4):1015–23.
Google Scholar
Ku EJ, Lee D-H, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: a 52-week prospective observational study. Diabetes Res Clin Pract. 2019;151:65–73.
Google Scholar
Ku EJ, Lee D-H, Jeon HJ, Oh TK. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Res Clin Pract. 2021;182:109123.
Google Scholar
Lin Y-H, Huang Y-Y, Hsieh S-H, Sun J-H, Chen S-T, Lin C-H. Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages. Front Endocrinol. 2019;10:820.
Google Scholar
Bhosle D, Indurkar S, Quadri U, Chandekar B. A comparative study of efficacy and safety of different sodium glucose co-transporter 2 (SGLT-2) inhibitors in the management of patients with type II diabetes mellitus. J Assoc Phys India. 2022;70(6):11–2.
Intensive blood-glucose. Control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) Group. Lancet. 1998;352(9131):837–53.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.
Google Scholar
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.
Google Scholar
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.
Google Scholar
Song SO, Jung CH, Song YD, Park C-Y, Kwon H-S, Cha BS, Park J-Y, Lee K-U, Ko KS, Lee B-W. Background and data configuration process of a nationwide population-based study using the Korean national health insurance system. Diabetes Metab J. 2014;38(5):395–403.
Google Scholar
Choi E-K. Cardiovascular research using the korean national health information database. Korean Circulation Journal. 2020;50(9):754–72.
Google Scholar
Lee H, Park J-B, Hwang I-C, Yoon YE, Park HE, Choi S-Y, Kim Y-J, Cho G-Y, Han K, Kim H-K. Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naïve young adults: a nationwide cohort study. Eur J Prev Cardiol. 2020;27(8):870–81.
Google Scholar
Choi Y-J, Kim S-H, Kang S-H, Yoon C-H, Lee H-Y, Youn T-J, Chae I-H, Kim C-H. Reconsidering the cut-off diastolic blood pressure for predicting cardiovascular events: a nationwide population-based study from Korea. Eur Heart J. 2019;40(9):724–31.
Google Scholar
Park J, Kwon S, Choi E-K, Choi Y-j, Lee E, Choe W, Lee S-R, Cha M-J, Lim W-H, Oh S. Validation of diagnostic codes of major clinical outcomes in a national health insurance database. Int J Arrhythmia. 2019;20(1):1–7.
Google Scholar
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RH, Bonaca MP, Mosenzon O, Kato ET, Cahn A. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials. Circulation. 2019;139(17):2022–31.
Google Scholar
Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CS, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. J Am Heart Association. 2020;9(3):e014908.
Google Scholar
Shao S-C, Chang K-C, Hung M-J, Yang N-I, Chan Y-Y, Chen H-Y, Kao Yang Y-H, Lai EC-C. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. Cardiovasc Diabetol. 2019;18(1):1–15.
Google Scholar
Nakagaito M, Joho S, Ushijima R, Nakamura M, Kinugawa K. Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circulation Rep. 2019;1(10):405–13.
Google Scholar
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356–63.
Google Scholar
Liberale L, Kraler S, Puspitasari YM, Bonetti NR, Akhmedov A, Ministrini S, Montecucco F, Marx N, Lehrke M, Hartmann N-UK. SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation. Cardiovascular Res. 2023;119(3):843–56.
Google Scholar
Fujimoto N, Borlaug BA, Lewis GD, Hastings JL, Shafer KM, Bhella PS, Carrick-Ranson G, Levine BD. Hemodynamic responses to rapid saline loading: the impact of age, sex, and heart failure. Circulation. 2013;127(1):55–62.
Google Scholar
Dominguez Rieg JA, Rieg T. What does sodium-glucose co‐transporter 1 inhibition add: prospects for dual inhibition. Diabetes Obes Metabolism. 2019;21:43–52.
Google Scholar
Seidelmann SB, Feofanova E, Yu B, Franceschini N, Claggett B, Kuokkanen M, Puolijoki H, Ebeling T, Perola M, Salomaa V. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. J Am Coll Cardiol. 2018;72(15):1763–73.
Google Scholar
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39.
Google Scholar
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.
Google Scholar
Dyck JR, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, Zuurbier CJ. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol. 2022;167:17–31.
Google Scholar
